Skip to Content
  • Revenues ($M)$103,444
  • Revenue Percent Change35.4%
  • Profits ($M)$4,220
  • Profits Percent Change118.4%
  • Assets ($M)$68,782
  • Employees302,500
  • Market Value — as of March 31, 2016 ($M)$90,874
  • Previous Rank35
  • Morning Consult Brand Index
    A+

Walgreens Boots Alliance has not looked healthy lately. Its partnerships with scandal-plagued Silicon Valley unicorn Theranos and controversial drug company Valeant have led to countless embarrassing headlines. Its acquisition of smaller rival Rite Aid may force it to sell off more drugstores than it really wants to. All the while, the company is still working to integrate the Alliance Boots acquisition last year and the turnover of most of its c-level executives. Still, Walgreens size gives it enormous clout with drugmakers, and the Boots products have been a big shot in the arm for its beauty business, allowing it to fend off CVS’ big push in that area. And its generic drug distribution contract with AmerisourceBergen has allowed it keep costs in check by streamlining how its gets its supply of drugs.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Stefano Pessina
Sector
Food and Drug Stores
Industry
Food and Drug Stores
HQ Location
Deerfield, IL
Websitehttp://www.walgreensbootsalliance.com
Years on Fortune 500 List22
Employees302,500
Figures are for fiscal year ended Aug. 31, 2015., Reorganized as a holding company after acquiring the remaining 55% of Alliance Boots (Switzerland), Dec. 31, 2014. Prior year's figures are for Walgreen, now a subsidiary of the company.

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$103,44435.4%
Profits ($M)$4,220118.4%
Assets ($M)$68,782-
Total Stockholder Equity ($M)$30,861-
Market Value — as of March 31, 2016 ($M)$90,874-

Profit Ratios

Profit as % of Revenues4.1%
Profits as % of Assets6.1%
Profits as % of Stockholder Equity13.7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)4
EPS % Change (from 2014)100%
EPS % Change (5 year annual rate)13.5%
EPS % Change (10 year annual rate)10.2%

Total Return

Total Return to Investors (2015)13.6%
Total Return to Investors (5 year, annualized)19.5%
Total Return to Investors (10 year, annualized)8.6%